03:49 PM EST - Antibe Therapeutics Inc : said its Founder and Chief Scientific Officer, Dr. John Wallace, is the senior author of an article published this week in the prestigious scientific journal Proceedings of the National Academy of Science USA describing research that may lead to a significant improvement in the treatment of Crohn’s Disease and Ulcerative Colitis, collectively known as "inflammatory bowel disease". Antibe Therapeutics Inc
shares V.ATE are trading up $0.04 at $0.50.
